Amgen (NASDAQ:AMGN) Lowered to Strong Sell at BidaskClub

BidaskClub lowered shares of Amgen (NASDAQ:AMGN) from a sell rating to a strong sell rating in a research report sent to investors on Saturday morning, BidAskClub reports.

AMGN has been the subject of a number of other research reports. Oppenheimer upped their target price on shares of Amgen from to in a report on Tuesday, January 21st. Cfra upped their target price on shares of Amgen from $215.00 to $223.00 and gave the stock a hold rating in a report on Friday, January 31st. Evercore ISI raised shares of Amgen from an in-line rating to an outperform rating in a report on Tuesday, January 21st. Argus reaffirmed a buy rating and set a target price on shares of Amgen in a report on Thursday, February 6th. Finally, JPMorgan Chase & Co. reaffirmed a hold rating on shares of Amgen in a report on Sunday, February 2nd. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $237.33.

Shares of Amgen stock traded up $0.44 during trading hours on Friday, reaching $223.48. 1,611,960 shares of the company’s stock were exchanged, compared to its average volume of 2,605,618. Amgen has a 1 year low of $166.30 and a 1 year high of $244.99. The company has a market capitalization of $131.55 billion, a P/E ratio of 17.36, a price-to-earnings-growth ratio of 1.96 and a beta of 1.12. The business has a fifty day moving average of $233.43 and a two-hundred day moving average of $215.84. The company has a quick ratio of 1.16, a current ratio of 1.44 and a debt-to-equity ratio of 2.79.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, January 30th. The medical research company reported $3.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.47 by $0.17. Amgen had a net margin of 33.57% and a return on equity of 85.52%. The business had revenue of $6.20 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the prior year, the firm earned $3.42 earnings per share. The company’s revenue for the quarter was down .5% compared to the same quarter last year. As a group, research analysts predict that Amgen will post 15.59 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 14th will be issued a $1.60 dividend. The ex-dividend date is Thursday, February 13th. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.86%. This is a positive change from Amgen’s previous quarterly dividend of $1.45. Amgen’s dividend payout ratio is currently 43.18%.

In other Amgen news, EVP Jonathan P. Graham sold 9,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $230.54, for a total value of $2,074,860.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $233.72, for a total transaction of $99,331.00. Following the completion of the transaction, the director now directly owns 4,988 shares in the company, valued at approximately $1,165,795.36. The disclosure for this sale can be found here. Insiders sold 27,426 shares of company stock valued at $6,351,866 in the last three months. 0.25% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of AMGN. BlackRock Inc. grew its holdings in shares of Amgen by 3.4% in the second quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock valued at $8,793,346,000 after purchasing an additional 1,585,911 shares during the period. Envestnet Asset Management Inc. grew its holdings in shares of Amgen by 1.3% in the third quarter. Envestnet Asset Management Inc. now owns 484,456 shares of the medical research company’s stock valued at $93,747,000 after purchasing an additional 6,169 shares during the period. First Citizens Bank & Trust Co. grew its holdings in shares of Amgen by 0.9% in the third quarter. First Citizens Bank & Trust Co. now owns 6,939 shares of the medical research company’s stock valued at $1,343,000 after purchasing an additional 63 shares during the period. San Francisco Sentry Investment Group CA grew its holdings in shares of Amgen by 4.8% in the third quarter. San Francisco Sentry Investment Group CA now owns 2,529 shares of the medical research company’s stock valued at $489,000 after purchasing an additional 116 shares during the period. Finally, Endurance Wealth Management Inc. grew its holdings in shares of Amgen by 1.6% in the third quarter. Endurance Wealth Management Inc. now owns 31,366 shares of the medical research company’s stock valued at $6,070,000 after purchasing an additional 506 shares during the period. 76.69% of the stock is currently owned by institutional investors.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Further Reading: Understanding the different types of bonds

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.